Chemerin was comparable in male and female tumor patients in the whole cohort (p = 0.354) and in the individual subgroups (p = 0.976 for controls, p = 0.540 for CRC and p = 0.511 for HCC). This evidence concerns the gene RARRES2 and hepatocellular carcinoma.